Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-6016a Phase 1 SAD Study in Healthy Japanese Subjects
NCT04818398Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of prafnosbart in fibrodysplasia ossificans progressiva (FOP) (7 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Number of Participants Reporting Treatment-emergent Adverse Events. Started Apr 2021; status: completed.
02
Drugs
prafnosbart
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT04818398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04818398.